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OBJECTIVES: Generation of population cost estimates
for event-time data requires a sophisticated approach 
to account for the probability of incurring the event over
time. This research investigated the relationship of donor
and recipient factors with all-cause renal graft failure and
estimates of the cost of failure from a Medicare perspec-
tive. METHODS: A two-part econometric approach 
was used to determine Medicare claims attributable to all-
cause graft failure (including deaths). First, type-speciﬁc
hazard functions were estimated with Cox proportional
hazards models. Using data from USRDS for primary
renal transplants in adults between 1993-1998, we devel-
oped separate predictive models for transplants from
living and cadaveric donors after identifying covariates
associated with graft loss. Models were stratiﬁed by trans-
plant year and included donor and recipient characteris-
tics plus clinical variables including immunosuppression
therapies. Next, the log-transformed costs for patients
who experienced the event were modeled against the
covariates to estimate costs speciﬁcally associated with
failure at a given time point. For patients who did not
experience the event, predicted costs were generated
based on the model coefﬁcients and individual covariates.
Retransformation of the log costs included an adjustment
using residual smearing. The expected Medicare claims
associated with graft failure were calculated by combin-
ing the estimated cumulative hazards of graft failure with
the smeared estimate of the claims associated with the
event. RESULTS: For living donor transplants (N =
5831), expected Medicare claims attributed to renal
transplant graft failure were approximately $13,073 ±
$14,318 (median = $8,933; range = $560–$191,169) at
3 years post-transplant. For cadaveric donor transplants
(N = 22,941), the expected Medicare claims were 
approximately $15,075 ± $13,149 (median = $11,540;
range = $699–$214,184). CONCLUSIONS: These esti-
mates provide groundwork for population-based studies
to address the cost-effectiveness of various treatments to
delay or prevent graft loss. The method allows policy-
makers to assess population costs after taking into
account the probability of event occurrence.
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Healthcare resource utilization (HCRU) may be evaluated
through patient interviews in multicenter clinical trials
but the accuracy of self-reported data should be assessed.
OBJECTIVE: This study evaluated the consistency
between electronic record data and patient self-reported
HCRU for herpes zoster (HZ) through telephone inter-
views. METHODS: HZ patients (N = 116) were recruited
from a managed care organization in Boston. HZ-related
hospitalizations, Emergency Department (ED) visits, 
outpatient visits and telephone calls were compared 
separately, with further differentiation among outpatient
contacts with primary care providers and specialists.
Medication use comparisons were made for analgesics,
antivirals and other prescription medications. Judgments
of consistency were based on intraclass correlation 
coefﬁcients (ICC) unless data were sparse. RESULTS:
Two patients with HZ hospitalizations were found in the
electronic records versus three in the questionnaire. Four
patients with ED visits were found in the electronic
records versus 34 in the questionnaire. The ICC for 
outpatient visits was 0.46 (CI 0.06-0.85; nelectronic records =
268, nZHEQ = 265). The ICC for telephone calls was 0.51
(CI 0.06–0.96; nelectronic records = 87, nZHEQ = 110). By out-
patient provider type, the ICC ranged from 0.27 for
primary care visits to 0.84 for specialist visits. ICCs of
0.55, 0.64 and 0.56 were found for pain medications,
antiviral medications, and other medications, respec-
tively. CONCLUSION: Patient self-reported HCRU 
reasonably (ICC ≥ 0.4), but imperfectly matched the elec-
tronic records across most categories, with no systematic
bias observed. Patient misclassiﬁcation of urgent care
visits as ED visits may account for some of the observed
discrepancies between ED and primary care visits. This
study, which represents one of the ﬁrst efforts to evaluate
the design of a patient self-report HCRU questionnaire
for use in clinical trials, identiﬁed limitations to compar-
isons between the two types of data sources and offers
insight into potential improvements for the design and
validation of such questionnaires.
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OBJECTIVES: In economic and epidemiologic studies
utilizing longitudinal data, researchers often require a
ﬁxed follow-up period. By allowing differential follow-
up, researchers can eliminate one source of selection bias.
Our objective was to compare analyses of two study 
populations from the General Practice Research Database
(GPRD) differing only in length of follow-up time.
METHODS: Study population 1 (SP1; n = 28,643)
included patients with a given condition ﬁrst diagnosed
between June 1988 and February 1999. Study population
2 (SP2; n = 21,289) included only those patients in SP1
with at least a year of follow-up. Comorbid conditions,
resource use, and reasons for loss to follow-up were
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examined. RESULTS: Approximately 26% (n = 7,354) 
of patients in SP1 were excluded from SP2. Reasons 
for exclusion were death (22%), loss to follow-up (34%),
and right-censoring (44%). Age, gender, and calendar
year of the index event were not dramatically different
between the two populations. Both crude and age-
adjusted prevalence rates of most comorbid conditions at
index date were lower in SP2. Incidence rates showed a
similar pattern. Mortality was signiﬁcantly higher in SP1
(5.7 vs. 3.8/100PY; p < 0.05). There was a decrease in
the proportion of patients never treated with drugs for
the selected condition from 42% in SP1 to 36% in SP2.
Mean and median values for annualized rates were lower
in SP2, possibly indicating that some patients with higher
resource use were selectively excluded. CONCLUSIONS:
The impact of selection bias associated with deﬁning
patient cohorts based on minimum follow-up time affects
both economic and epidemiologic analyses. Overall, the
results of this study suggest that researchers should deﬁne
a cohort without regard to follow-up whenever possible.
The appropriate and necessary follow-up period will
clearly vary by condition and perhaps by local practice
patterns. The data themselves can help inform the appro-
priate time frame for follow-up.
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OBJECTIVES: Resource utilization of co-medication use
in clinical trials is often cumbersome because it involves
thousands of co-medications, which are not assigned
standard codes, such as National Drug Codes (NDC),
making analysis difﬁcult at the individual drug level. We
developed an automated routine that allowed each 
co-medication to be matched to published NDC prices,
in turn allowing, costing at the individual drug level.
METHODS: Computer-based automated mapping rou-
tines (SAS, v8.2) were developed to handle co-medication
trial data collected using the World Health Organization’s
(WHO) Anatomical Therapeutic Chemical (ATC) classi-
ﬁcation system, along with the daily dose. Our approach
was to map the ATC code descriptions to their generic
names, and merge these with those in the Food and Drug
Administration’s (FDA) NDC table, thereby obtaining 
the NDC for each co-medication used. An average cost
was calculated by averaging the average wholesale 
price (AWP) per milligram for each NDC that matched
the generic names. The average daily cost for the co-
medications was then calculated by multiplying the daily
dose by the average costs. RESULTS: A random sample
of 1000 observations of co-medications data was drawn
from a randomized cardiovascular trial. This sample 
contained 238 unique WHO ATC codes. Our computer-
based automated procedures matched 209; i.e., about
88% of the codes. This translated into 956 out of the
1000 observations being matched (96%). Comparing the
entire trial dataset with NDC table showed a 92% match.
CONCLUSIONS: The proposed methodology provides
an automated routine allowing WHO ATC coded co-
medications to be transcribed to unique NDC codes. This
methodology can also be extended to handle medications
described as generic or brand names in any format. This
allows co-medication costs to be assigned at the individ-
ual drug level, improving the feasibility and rigor of
within-trial economic analysis.
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OBJECTIVE: The objectives of this study were to
measure diabetic patients’ quality-of-life (QOL), utility,
and willingness-to-pay (WTP), and to examine the 
interrelationship between these measures. METHODS:
Diabetic patients ≥18 years old were randomly selected
from 2 hospital endocrinology clinics. Patients were inter-
viewed to measure utility values using a visual analogue
scale (VAS) and standard gamble (SG), and measure WTP
for pharmacist-provided education using contingent 
valuation. QOL was measured via self-administered 
questionnaire containing the 36-item Short-Form health
survey (SF-36), Diabetes Quality of Life instrument
(DQOL), and Health Utility Index (HUI). Relationships
between scales of QOL instruments, utilities, and WTP
were tested using Spearman’s correlation coefﬁcients and
regression analysis, and differences by study variables
were tested using t-tests and analysis of variance.
RESULTS: Two-hundred eighty-three patients completed
the interview and questionnaire. Mean health-utility was
0.72 from VAS, 0.83 from SG, 0.83 from HUI2 and 0.73
from HUI3. Mean scores for SF-36 physical component
(PCS) and mental component (MCS) were 45.4 and 50.2,
respectively, and mean score for total DQOL was 0.70.
Patients’ mean WTP was $32.65. Age and number of dia-
betic complications were signiﬁcant factors for VAS. The
PCS and MCS were both signiﬁcantly positively corre-
lated with total DQOL, HUI2, HUI3, and VAS (all p <
0.0001), but not SG or WTP. VAS and total DQOL were
signiﬁcantly correlated with each other, SF-36 subscales,
HUI2, HUI3, and SG (all p < 0.05), except for WTP. WTP
was neither signiﬁcantly correlated with any utility values
(VAS, SG, HUI2, and HUI3) nor any QOL measures 
(SF-36 and total DQOL), but correlations were in the
expected directions. CONCLUSIONS: The DQOL
demonstrated strong correlation with SF-36 and utility
values measured using VAS, SG, and HUIs, but weak 
correlation with WTP. Further research is warranted to
